Diagnostic value of HSP90α and Related Markers in Lung Cancer

Abstract Aim: To prove the expression of heat shock protein 90α (HSP90α) in lung cancer and the clinical value of HSP90α and related markers in the diagnosis of lung cancer. Methods: The concentrations of HSP90α and related markers were detected in the blood of 560 lung cancer patients by enzyme-linked immunosorbent assay for analyzing the statistical differences of HSP90α in patients' age, gender, pathological types, tumour staging and metastasis status, as well as the differences and evaluate the value of HSP90α and related markers in lung cancer diagnosis. Results: The results showed no statistical difference in HSP90α among age and gender groups (P>0.05); In the group by lung cancer type, statistical differences were found in the HSP90α level between the small cell lung cancer (SCLC) group and the squamous carcinoma (SLC) group (P<0.05); In the group by staging, the HSP90α level of high staging was significantly higher than that low staging, and the HSP90α level at Ⅰ/Ⅱ/Ⅲ/Ⅳ shows statistical differences among the groups (P<0.05); The test result of HSP90α was higher in the metastatic group than in the non-metastatic group significantly, and the significant difference between the two groups (P<0.05). The r value of the HSP90α and related markers in the diagnosis of lung cancer: NSE>CEA>ProGRP>CF211 (P<0.05). Although HSP90α and related markers didn’t fit the satisfactory conformance, in terms of the positive rate of diagnosis, it were statistically differences in the diagnostic positive rate between HSP90α and each marker (P<0.01). Reducing HSP90α clinical references in lung cancer combined diagnosis can effectively improve the positive rate of the combined diagnosis. Conclusion: HSP90α has significant value on early screening and diagnosis of lung cancer. The combined application of HSP90α and related markers can improve the positive rate of early diagnosis of lung cancer effectively.

Download Full-text

Diagnostic value of HSP90α and Related Markers in Lung Cancer

10.21203/rs.2.10011/v4 ◽

2019 ◽

Author(s):

Zhimin Yuan ◽

Songlin Hong ◽

Lin Li ◽

Lin He ◽

Peng Xiao ◽

...

Keyword(s):

Lung Cancer ◽

Squamous Carcinoma ◽

Diagnostic Value ◽

Enzyme Linked Immunosorbent Assay ◽

Cancer Type ◽

Clinical Value ◽

Early Screening ◽

Significant Difference ◽

Positive Rate ◽

Diagnosis Of Lung Cancer

Abstract Aim: To prove the expression of heat shock protein 90α (HSP90α) in lung cancer and the clinical value of HSP90α and related markers in the diagnosis of lung cancer. Methods: The concentrations of HSP90α and related markers were detected in the blood of 560 lung cancer patients by enzyme-linked immunosorbent assay for analyzing the statistical differences of HSP90α in patients' age, gender, pathological types, tumour staging and metastasis status, as well as the differences and evaluate the value of HSP90α and related markers in lung cancer diagnosis. Results: The results showed no statistical difference in HSP90α among age and gender groups (P>0.05); In the group by lung cancer type, statistical differences were found in the HSP90α level between the small cell lung cancer (SCLC) group and the squamous carcinoma (SLC) group (P<0.05); In the group by staging, the HSP90α level of high staging was significantly higher than that low staging, and the HSP90α level at Ⅰ/Ⅱ/Ⅲ/Ⅳ shows statistical differences among the groups (P<0.05); The test result of HSP90α was higher in the metastatic group than in the non-metastatic group significantly, and the significant difference between the two groups (P<0.05). The r value of the HSP90α and related markers in the diagnosis of lung cancer: NSE>CEA>ProGRP>CF211 (P<0.05). Although HSP90α and related markers didn’t fit the satisfactory conformance, in terms of the positive rate of diagnosis, it were statistically differences in the diagnostic positive rate between HSP90α and each marker (P<0.01). Reducing HSP90α clinical references in lung cancer combined diagnosis can effectively improve the positive rate of the combined diagnosis. Conclusion: HSP90α has significant value on early screening and diagnosis of lung cancer. The combined application of HSP90α and related markers can improve the positive rate of early diagnosis of lung cancer effectively.

Download Full-text

Diagnostic value of HSP90α and Related Markers in Lung Cancer

10.21203/rs.2.10011/v3 ◽

2019 ◽

Author(s):

Zhimin Yuan ◽

Songlin Hong ◽

Lin Li ◽

Lin He ◽

Peng Xiao ◽

...

Keyword(s):

Lung Cancer ◽

Squamous Carcinoma ◽

Diagnostic Value ◽

Enzyme Linked Immunosorbent Assay ◽

Cancer Type ◽

Clinical Value ◽

Early Screening ◽

Significant Difference ◽

Positive Rate ◽

Diagnosis Of Lung Cancer

Abstract Aim: To prove the expression of heat shock protein 90α (HSP90α) in lung cancer and the clinical value of HSP90α and related markers in the diagnosis of lung cancer. Methods: The concentrations of HSP90α and related markers were detected in the blood of 560 lung cancer patients by enzyme-linked immunosorbent assay for analyzing the statistical differences of HSP90α in patients' age, gender, pathological types, tumour staging and metastasis status, as well as the differences and evaluate the value of HSP90α and related markers in lung cancer diagnosis. Results: The results showed no statistical difference in HSP90α among age and gender groups (P>0.05); In the group by lung cancer type, statistical differences were found in the HSP90α level between the small cell lung cancer (SCLC) group and the squamous carcinoma (SLC) group (P<0.05); In the group by staging, the HSP90α level of high staging was significantly higher than that low staging, and the HSP90α level at Ⅰ/Ⅱ/Ⅲ/Ⅳ shows statistical differences among the groups (P<0.05); The test result of HSP90α was higher in the metastatic group than in the non-metastatic group significantly, and the significant difference between the two groups (P<0.05). The r value of the HSP90α and related markers in the diagnosis of lung cancer: NSE>CEA>ProGRP>CF211 (P<0.05). Although HSP90α and related markers didn’t fit the satisfactory conformance, in terms of the positive rate of diagnosis, it were statistically differences in the diagnostic positive rate between HSP90α and each marker (P<0.01). Reducing HSP90α clinical references in lung cancer combined diagnosis can effectively improve the positive rate of the combined diagnosis. Conclusion: HSP90α has significant value on early screening and diagnosis of lung cancer. The combined application of HSP90α and related markers can improve the positive rate of early diagnosis of lung cancer effectively.

Download Full-text

Diagnostic Value of HSP90α and Related Markers in Lung Cancer

10.21203/rs.3.rs-181774/v1 ◽

2021 ◽

Author(s):

zhimin yuan ◽

longhao wang ◽

songlin hong ◽

lin li ◽

ting tang ◽

...

Keyword(s):

Lung Cancer ◽

Squamous Carcinoma ◽

Diagnostic Value ◽

Enzyme Linked Immunosorbent Assay ◽

Cancer Type ◽

Clinical Value ◽

Early Screening ◽

Combined Application ◽

Positive Rate ◽

Diagnosis Of Lung Cancer

Abstract PurposeTo investigate the expression of heat shock protein 90α (HSP90α) in patients with lung cancer and the clinical value of HSP90α and other related markers in the diagnosis of lung cancer.MethodsThe plasma levels of HSP90α and related markers (CEA, NSE, CF211 and ProGRP) were detected in the blood of 560 patients with lung cancer by ELISA (enzyme-linked immunosorbent assay). Groups were divided according to the gender (male/female), age (age≤40, 41<age≤50, 51<age≤60, 61<age≤70 and age>70), types of lung cancer (small-cell, squamous carcinoma, adenocarcinoma, hybrid and other type), staging (Ⅰ, Ⅱ, Ⅲ and Ⅳ) and metastasis (metastasis and non-metastasis) separately. Wilcoxon Mann-Whitney test and Kruskal-Wallis test were used to compare statistical differences between two groups/among the multiple groups for each factor of HSP90α.ResultsNo statistical difference was found in plasma level of HSP90α among different age and gender groups (P> 0.05). In the group divided by lung cancer type, staging and metastasis status, there were statistical differences among different groups in HSP90α level (P< 0.05). R values of HSP90α correlated with other related markers in the diagnosis of lung cancer (P< 0.05). Although HSP90α and other related markers didn’t fit the satisfactory conformance, in terms of the positive rate of diagnosis, it was statistically differences in the diagnostic positive rate between HSP90α and each marker (P< 0.01). Reduced cut-off value of HSP90α in lung cancer can effectively improve the positive rate of diagnosis when combined with other tumor biomarkers.ConclusionsHSP90α has significant clinical value on early screening and diagnosis of lung cancer. The combined application of HSP90α and related markers can improve the positive rate of early diagnosis of lung cancer effectively.

Download Full-text

Autoantibody Signatures Discovered by HuProt Protein Microarray to Enhance the Diagnosis of Lung Cancer

10.21203/rs.3.rs-1104087/v1 ◽

2021 ◽

Author(s):

Yulin Wang ◽

Jiaqi Li ◽

Xue Zhang ◽

Man Liu ◽

Longtao Ji ◽

...

Keyword(s):

Lung Cancer ◽

Validation Cohort ◽

Mediastinal Lymph Node ◽

Protein Microarray ◽

Characteristic Curve ◽

Pulmonary Nodules ◽

Diagnostic Value ◽

Enzyme Linked Immunosorbent Assay ◽

Significant Difference ◽

Diagnosis Of Lung Cancer

Abstract Background: This study aims to comprehensively discover novel autoantibodies (TAAbs) against tumor-associated antigens (TAAs) and establish diagnostic models for assisting in the diagnosis of lung cancer (LC) and discrimination of pulmonary nodules (PN).Methods: HuProt human microarray was used to discover the candidate TAAs and Enzyme-linked immunosorbent assay (ELISA) was performed to detect the level of TAAbs in 634 participants of two independent validation cohorts. Logistic regression analysis was used to construct models. Receiver operating characteristic curve (ROC) analysis was utilized to assess the diagnostic value of models.Results: Eleven TAAs were discovered by means of protein microarray and data analysis. The level of ten TAAbs (anti-SARS, anti-ZPR1, anti-FAM131A, anti-GGA3, anti-PRKCZ, anti-HDAC1, anti-GOLPH3, anti-NSG1, anti-CD84 and anti-EEA1) was higher in LC patients than that in NC of validation cohort 1 (P<0.05). The model 1 comprising 4 TAAbs (anti-ZPR1, anti-PRKCZ, anti-NSG1 and anti-CD84) and CEA reached an AUC of 0.813 (95%CI: 0.762-0.864) for diagnosing LC from normal individuals. 5 of 10 TAAbs (anti-SARS, anti-GOLPH3, anti-NSG1, anti-CD84 and anti-EEA1) existed a significant difference between malignant pulmonary nodules (MPN) and benign pulmonary nodules (BPN) patients in validation cohort 2 (P<0.05). Model 2 consisting of anti-EEA1, traditional biomarkers (CEA, CYFRA211 and CA125) and 3 CT characteristics (vascular notch sign, lobulation sign, mediastinal lymph node enlargement) could distinguish MPN from BPN patients with an AUC of 0.845 (sensitivity: 58.3%, specificity: 96.6%).Conclusions: High-throughput protein microarray is an efficient approach to discovering novel TAAbs which could increase the accuracy of lung cancer diagnosis in the clinic.

Download Full-text

Clinical value of tumor-associated antigens and autoantibody panel combination detection in the early diagnostic of lung cancer

Cancer Biomarkers ◽

10.3233/cbm-210099 ◽

2021 ◽

pp. 1-9

Author(s):

Renren Ouyang ◽

Shiji Wu ◽

Bo Zhang ◽

Ting Wang ◽

Botao Yin ◽

...

Keyword(s):

Lung Cancer ◽

Lung Disease ◽

Cytokeratin 19 ◽

Healthy Controls ◽

Control Groups ◽

Clinical Value ◽

Tumor Associated Antigens ◽

Pathological Subtype ◽

Positive Rate ◽

Diagnosis Of Lung Cancer

BACKGROUND: This study aimed to investigate the efficiency of combining tumor-associated antigens (TAAs) and autoantibodies in the diagnosis of lung cancer. METHODS: The serum levels of TAAs and seven autoantibodies (7-AABs) were detected from patients with lung cancer, benign lung disease and healthy controls. The performance of a new panel by combing TAAs and 7-AABs was evaluated for the early diagnosis of lung cancer. RESULTS: The positive rate of 7-AABs was higher than the single detection of antibody. The positive rate of the combined detection of 7-AABs in lung cancer group (30.2%) was significantly higher than that of healthy controls (16.8%), but had no statistical difference compared with that of benign lung disease group (20.8%). The positive rate of 7-AABs showed a tendency to increase in lung cancer patients with higher tumor-node-metastasis (TNM) stages. For the pathological subtype analysis, the positive rate of 7-AABs was higher in patients with squamous cell carcinoma and small cell lung cancer than that of adenocarcinoma. The levels of carcinoembryonic antigen (CEA) and cytokeratin 19 fragment 211 (CYFRA 211) were significantly higher than that of benign lung disease and healthy control groups. An optimal model was established (including 7-AABs, CEA and CYFRA21-1) to distinguish lung cancer from control groups. The performance of this model was superior than that of single markers, with a sensitivity of 52.26% and specificity of 77.46% in the training group. Further assessment was studied in another validation group, with a sensitivity of 44.02% and specificity of 83%. CONCLUSIONS: The diagnostic performance was enhanced by combining 7-AABs, CEA and CYFRA21-1, which has critical value for the screening and early detection of lung cancer.

Download Full-text

Values of different specimen preparation methods for the diagnosis of lung cancer by endobronchial ultrasound guided transbronchial needle aspiration

10.21203/rs.2.12005/v1 ◽

2019 ◽

Author(s):

YouZu Xu ◽

Jian Lin ◽

meifang chen ◽

HaiHong Zheng ◽

JiaXi Feng

Keyword(s):

Lung Cancer ◽

Needle Aspiration ◽

Endobronchial Ultrasound ◽

Ultrasound Guided ◽

Transbronchial Needle Aspiration ◽

Hilar Lymph Node ◽

Treatment Type ◽

Significant Difference ◽

Positive Rate ◽

Diagnosis Of Lung Cancer

Abstract Background: Endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) has been become an important procedure for the diagnosis and staging of lung cancer. Our research identified the effects of different pathological preparation on the diagnosis of lung cancer for specimens obtained by biopsy. Methods: Patients were clinically considered if lung cancer was accompanied by mediastinal or hilar lymph node enlargement between March 2014 and November 2017. Specimens obtained by EBUS-TBNA were treated by three methods: traditional smear cytology, liquid-based cytology (LBC) and histopathology. Results: Of a total of 154 puncture sites from 153 patients, the total positive rate of combination for the three pathological treatment types (histopathology, direct traditional smear, and LBC) was 77.3%. The diagnostic positive rate for histopathology was 68.6%, direct traditional smear was 65.6%, and LBC was 60.4%; there was no significant differences among the three single pathological treatment types (P=0.29), but there was a statistically significant difference between the combination of three treatments and any single pathological treatment type (P=0.01). The diagnostic sensitivities of histopathology combined with traditional smear and histopathology combined LBC were 94.4% and 92.8%, respectively, the specificities and PPVs were both 100%, and the diagnostic accuracies were 95.5% and 94.2%, respectively; the sensitivities, specificities and diagnostic accuracies above were all higher than those of single specimen treatment and lower than those of the three combined. Conclusion: When EBUS-TBNA is used for the diagnosis and staging of lung cancer, the use of histopathological sections combined with direct cytological smear should be sufficient and is the most economical choice.

Download Full-text

Values of different specimen preparation methods for the diagnosis of lung cancer by endobronchial ultrasound guided transbronchial needle aspiration

10.21203/rs.2.12005/v2 ◽

2020 ◽

Author(s):

YouZu Xu ◽

Jian Lin ◽

meifang chen ◽

HaiHong Zheng ◽

JiaXi Feng

Keyword(s):

Lung Cancer ◽

Needle Aspiration ◽

Endobronchial Ultrasound ◽

Ultrasound Guided ◽

Transbronchial Needle Aspiration ◽

Hilar Lymph Node ◽

Treatment Type ◽

Significant Difference ◽

Positive Rate ◽

Diagnosis Of Lung Cancer

Abstract Background: Endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) has been become an important procedure for the diagnosis and staging of lung cancer. Our research identified the effects of different pathological preparation on the diagnosis of lung cancer for specimens obtained by biopsy. Methods: Patients were clinically considered if lung cancer was accompanied by mediastinal or hilar lymph node enlargement between March 2014 and November 2017. Specimens obtained by EBUS-TBNA were treated by three methods: traditional smear cytology, liquid-based cytology (LBC) and histopathology. Results: Of a total of 154 puncture sites from 153 patients, the total positive rate of combination for the three pathological treatment types (histopathology, direct traditional smear, and LBC) was 77.3%. The diagnostic positive rate for histopathology was 68.6%, direct traditional smear was 65.6%, and LBC was 60.4%; there was no significant differences among the three single pathological treatment types (P=0.29), but there was a statistically significant difference between the combination of three treatments and any single pathological treatment type (P=0.01). The diagnostic sensitivities of histopathology combined with traditional smear and histopathology combined LBC were 94.4% and 92.8%, respectively, the specificities and PPVs were both 100%, and the diagnostic accuracies were 95.5% and 94.2%, respectively; the sensitivities, specificities and diagnostic accuracies above were all higher than those of single specimen treatment and lower than those of the three combined. Conclusion: When EBUS-TBNA is used for the diagnosis and staging of lung cancer, the use of histopathological sections combined with direct cytological smear should be sufficient and is the most economical choice.

Download Full-text

Serological Evidence of Filovirus Infection in Nonhuman Primates in Zambia

Viruses ◽

10.3390/v13071283 ◽

2021 ◽

Vol 13 (7) ◽

pp. 1283

Author(s):

Katendi Changula ◽

Edgar Simulundu ◽

Boniface Pongombo Lombe ◽

Eri Nakayama ◽

Hiroko Miyamoto ◽

...

Keyword(s):

Nonhuman Primates ◽

Hemorrhagic Fever ◽

Enzyme Linked Immunosorbent Assay ◽

Vervet Monkeys ◽

Intermediate Hosts ◽

Significant Difference ◽

Positive Rate ◽

Antibody Titers ◽

Potential Risks ◽

Reston Virus

Ebolaviruses and marburgviruses are filoviruses that are known to cause severe hemorrhagic fever in humans and nonhuman primates (NHPs). While some bat species are suspected to be natural reservoirs of these filoviruses, wild NHPs often act as intermediate hosts for viral transmission to humans. Using an enzyme-linked immunosorbent assay, we screened two NHP species, wild baboons and vervet monkeys captured in Zambia, for their serum IgG antibodies specific to the envelope glycoproteins of filoviruses. From 243 samples tested, 39 NHPs (16%) were found to be seropositive either for ebolaviruses or marburgviruses with endpoint antibody titers ranging from 100 to 25,600. Interestingly, antibodies reactive to Reston virus, which is found only in Asia, were detected in both NHP species. There was a significant difference in the seropositivity for the marburgvirus antigen between the two NHP species, with baboons having a higher positive rate. These results suggest that wild NHPs in Zambia might be nonlethally exposed to these filoviruses, and this emphasizes the need for continuous monitoring of filovirus infection in wild animals to better understand the ecology of filoviruses and to assess potential risks of outbreaks in humans in previously nonendemic countries.

Download Full-text

A new exploration of white globe appearance (WGA) in ulcerative lesions

Zeitschrift für Gastroenterologie ◽

10.1055/a-1200-2287 ◽

2020 ◽

Vol 58 (08) ◽

pp. 754-760

Author(s):

Jinnian Cheng ◽

Jie Xia ◽

Qian Zhuang ◽

Xianjun Xu ◽

Xiaowan Wu ◽

...

Keyword(s):

Narrow Band ◽

Narrow Band Imaging ◽

Diagnostic Value ◽

Imaging Data ◽

Clinical Value ◽

Significant Difference ◽

Cancerous Lesions ◽

Ulcerative Lesions ◽

Reliable Marker ◽

Tree Branch

Abstract Aim White globe appearance (WGA), a small white lesion with a globular shape that can be clearly visualized by magnifying endoscopy with narrow-band imaging (ME-NBI), was reported to be a reliable marker of early gastric cancer (EGC). However, we found that this endoscopic presentation could also be seen in non-cancerous tissues, especially in ulcerative lesions. This study aimed to further investigate the diagnostic value of WGA in differentiating non-cancerous lesions from EGC in ulcer-type cases. Materials and Methods We retrospectively reviewed 54 cases of EGC and 155 cases of non-cancerous lesions in this study, all of which had endoscopic imaging data of ME-NBI scanning and pathological data of biopsy or resected specimens. The correlation of the prevalence of WGA and ulcerative lesions, as well as the characteristics of WGA between the 2 groups were analyzed in this study. Results WGA was more common in ulcerative lesions (27.6 %, 21/76) than in non-ulcerative lesions (3.8 %, 5/133) (p < 0.001) in our study. In the ulcerative cases, no significant difference in prevalence of WGA was observed between EGC and non-cancerous lesions (p = 0.532). Compared with WGA in EGC, WGA in non-cancerous lesions tended to show the characteristic of tree-branch-like vessels on globular shape (p < 0.001). Conclusions WGA is more likely to occur in ulcerative lesions, and the presence of WGA alone cannot distinguish EGC from non-cancerous lesions in ulcer-type cases. In WGA-positive tissue, tree-branch-like vessels of globular shape may provide a certain clinical value in diagnosis of non-cancerous lesions or EGC.

Download Full-text